Junshi biological terminates its cooperation with AstraZeneca

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

NaaS and NewLink Partnered with China Construction Bank to Progress New Energy Globally

This strategic partnership is to empower NewLink and NaaS to expand their global presence in the new energy sector, thereby fostering green, low-carbon, and sustainable development in the energy industry.

2022 ESG Report Analysis | Yili: The Practical Path of ESG

Yili, a leading company in China's dairy industry, recently released the 2022 Sustainable Development Report.

"TopXGun" and "Xingchen Dahai" have both recently closed funding rounds

EqualOcean has learned that recently, TopXGun(拓攻机器人), a civilian manufacturer of large-scale UAVs, announced that it has received C1 round of equity financing led by Archaeus Capital(含元资本). In addition, Hangzhou Xingchen Dahai Technology Co., Ltd (杭州星辰大海科技有限公司)(hereinafter referred to as "Xingchen Dahai"), a technology company focusing on the field of drone countermeasures, has completed tens of millions of dollars of Series A financing.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.